Weekly CEO Buys Highlight: CLMS, OPK, OVAS, RTRX, MDCA

Author's Avatar
Mar 17, 2014

According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below:

Calamos Asset Management Inc. (CLMS, Financial): Chairman, CEO and Global Co-CIO, 10% Owner John P. Calamos Sr. Bought 225,004 Shares

Chairman, CEO and Global Co-CIO, 10% Owner of Calamos Asset Management Inc. (CLMS, Financial) John P. Calamos Sr. bought 225,004 shares during the past week at an average price of $12.64. Calamos Asset Management Inc. is a global asset management firm that offers strategies to fulfill a range of asset allocation goals through a multi-team platform. Calamos Asset Management Inc. has a market cap of $259.508 million; its shares were traded at around $12.64 with a P/E ratio of 21.10 and P/S ratio of 0.94. The dividend yield of Calamos Asset Management Inc. stocks is 3.96%.

Mario Gabelli (Trades, Portfolio) owns 126,000 shares as of 12/31/2013, which accounts for 0.008% of the $18.65 billion portfolio of GAMCO Investors.

SVP and CFO Nimish S. Bhatt bought 337 shares of CLMS stock on 02/25/2014 at the average price of $11.45. Nimish S. Bhatt owns at least 88,689 shares after this. The price of the stock has increased by 10.39% since.

Opko Health Inc. (OPK, Financial): CEO & Chairman, 10% Owner Phillip Frost Md Et Al Bought 123,500 Shares

CEO and Chairman, 10% Owner of Opko Health Inc. (OPK) Phillip Frost Md Et Al bought 123,500 shares during the past week at an average price of $9.66. Opko Health Inc. was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics Inc. Opko Health Inc. has a market cap of $3.99 billion; its shares were traded at around $9.66 with and P/S ratio of 34.50. Opko Health Inc. had an annual average earnings growth of 4.40% over the past 10 years.

Opko recently reported its fourth quarter and full year 2013 financial results. For the fourth quarter of 2013, consolidated revenues increased about 30% to $20.7 million from $16.2 million in the prior year period. For the year ended Dec. 31, 2013, consolidated revenues more than doubled to $96.5 million from $47.0 million in the prior year.

George Soros (Trades, Portfolio) owns 844,600 shares as of 12/31/2013, an increase of 13.37% from the previous quarter. This position accounts for 0.061% of the $11.78 billion portfolio of Soros Fund Management LLC. Mario Gabelli (Trades, Portfolio) owns 15,000 shares as of 12/31/2013, which accounts for 0.0007% of the $18.65 billion portfolio of GAMCO Investors.

Vice Chairman and CTO Jane Hsiao Ph.D. bought 10,000 shares of OPK stock on 01/30/2014 at the average price of $8.14. Jane Ph D Hsiao owns at least 36,818,758 shares after this. The price of the stock has increased by 18.67% since.

OvaScience Inc. (OVAS, Financial): President and CEO, 10% Owner Michelle Dipp Bought 100,000 Shares

President and CEO, 10% Owner of OvaScience Inc. (OVAS, Financial) Michelle Dipp bought 100,000 shares on 03/07/2014 at an average price of $10.26. OvaScience Inc. was established in 2011 & is based in Cambridge, Mass. Ovascience Inc. has a market cap of $190.459 million.

OvaScience recently reported its fourth quarter 2013 financial results. Net loss for the three months ended Dec. 31, 2013 was $11.0 million, or ($0.64) per share, as compared to net loss of $4.2 million, or ($0.33) per share, for the three months ended Dec. 31, 2012.

Director, 10% Owner Christoph H. Westphal bought 100,000 shares of OVAS stock on 03/07/2014 at the average price of $10. Christoph H. Westphal owns at least 4,527,348 shares after this. The price of the stock has increased by 2.6% since.

Retrophin Inc. (RTRX, Financial): CEO, 10% Owner Martin Shkreli Bought 40,658 Shares

CEO, 10% Owner of Retrophin Inc. (RTRX, Financial) Martin Shkreli bought 40,658 shares during the past week at an average price of $17.35. Pivotal Therapeutics Inc. is engaged in the development of pharmaceutical products for the treatment of rare diseases. Retrophin Inc. has a market cap of $402.44 million; its shares were traded at around $17.35 .

Director Cornelius E. Golding bought 3,000 shares of RTRX stock on 12/24/2013 at the average price of $7.5. Cornelius E. Golding owns at least 3,000 shares after this.

MDC Partners Inc. (MDCA, Financial): Chairman, CEO and President, 10% Owner Miles Nadal Bought 30,000 Shares

Chairman, CEO and President, 10% Owner of MDC Partners Inc. (MDCA) Miles Nadal bought 30,000 shares during the past week at an average price of $21.17. MDC Partners Inc. was formed by Certificate of Amalgamation effective Dec. 19, 1986, pursuant to the Business Corporations Act (Ontario). MDC Partners Inc. has a market cap of $1.06 billion; its shares were traded at around $21.17 with and P/S ratio of 0.88. The dividend yield of MDC Partners Inc. stocks is 3.02%.

Joel Greenblatt (Trades, Portfolio) owns 18,416 shares as of 12/31/2013, an increase of 63.73% from the previous quarter. This position accounts for 0.011% of the $4.2 billion portfolio of Gotham Capital. Mario Gabelli (Trades, Portfolio) owns 16,500 shares as of 12/31/2013, which accounts for 0.0023% of the $18.65 billion portfolio of GAMCO Investors.

CFO David B. Doft bought 1,000 shares of MDCA stock on 03/12/2014 at the average price of $21.5. David B. Doft owns at least 163,619 shares after this. The price of the stock has decreased by 1.53% since.